Aethlon Medical to Release Fiscal First Quarter Financial Results and Host Conference Call on August 13, 2025
Aethlon Medical (Nasdaq: AEMD), a clinical-stage medical device company, will release its fiscal Q1 2025 financial results on August 13, 2025 at 4:15 p.m. ET, followed by a conference call at 4:30 p.m. ET.
The company's main product, the 贬别尘辞辫耻谤颈蹿颈别谤庐, is an investigational medical device designed to remove enveloped viruses and tumor-derived extracellular vesicles from circulation. The device holds FDA Breakthrough Device Designation for treating advanced cancer patients unresponsive to standard therapy and life-threatening viruses without approved treatments.
Aethlon Medical (Nasdaq: AEMD), un'azienda di dispositivi medici in fase clinica, pubblicher脿 i risultati finanziari del primo trimestre fiscale 2025 il 13 agosto 2025 alle 16:15 ET, seguiti da una conferenza telefonica alle 16:30 ET.
Il prodotto principale dell'azienda, il 贬别尘辞辫耻谤颈蹿颈别谤庐, 猫 un dispositivo medico sperimentale progettato per rimuovere virus incapsulati e vescicole extracellulari derivate da tumori dalla circolazione. Il dispositivo ha ottenuto la Designazione di Dispositivo Rivoluzionario dalla FDA per il trattamento di pazienti con cancro avanzato non responsivi alle terapie standard e per virus pericolosi per la vita senza trattamenti approvati.
Aethlon Medical (Nasdaq: AEMD), una empresa de dispositivos m茅dicos en etapa cl铆nica, publicar谩 sus resultados financieros del primer trimestre fiscal de 2025 el 13 de agosto de 2025 a las 4:15 p.m. ET, seguido de una llamada de conferencia a las 4:30 p.m. ET.
El producto principal de la compa帽铆a, el 贬别尘辞辫耻谤颈蹿颈别谤庐, es un dispositivo m茅dico en investigaci贸n dise帽ado para eliminar virus envueltos y ves铆culas extracelulares derivadas de tumores de la circulaci贸n. El dispositivo cuenta con la Designaci贸n de Dispositivo Innovador de la FDA para tratar a pacientes con c谩ncer avanzado que no responden a terapias est谩ndar y virus potencialmente mortales sin tratamientos aprobados.
Aethlon Medical (雮橃姢雼�: AEMD)鞚� 鞛勳儊 雼硠 鞚橂旮瓣赴 須岇偓搿�, 2025 須岅硠鞐半弰 1攵勱赴 鞛 瓴瓣臣毳� 2025雲� 8鞗� 13鞚� 鞓ろ泟 4鞁� 15攵�(霃欕秬鞁滉皠)鞐� 氚滍憸頃橂┌, 鞚挫柎靹� 鞓ろ泟 4鞁� 30攵�(霃欕秬鞁滉皠)鞐� 旎嵓霟办姢 旖滌潉 歆勴枆頃� 鞓堨爼鞛呺媹雼�.
須岇偓鞚� 欤检殧 鞝滍拡鞚� 贬别尘辞辫耻谤颈蹿颈别谤庐電� 靾滍櫂 欷戩澑 鞕疙敿 氚旍澊霟姢鞕� 膦呾枒 鞙犽灅 靹疙彫鞕� 靻岉彫毳� 鞝滉卑頃橂弰搿� 靹り硠霅� 鞛勳儊 鞁滍棙 欷戩澑 鞚橂旮瓣赴鞛呺媹雼�. 鞚� 旮瓣赴電� 響滌 旃橂鞐� 氚橃潙頃橃 鞎婋姅 歆勴枆靹� 鞎� 頇橃瀽鞕� 鞀轨澑霅� 旃橂氩曥澊 鞐嗠姅 靸濍獏鞚� 鞙勴槕頃橂姅 氚旍澊霟姢毳� 旃橂頃橁赴 鞙勴暣 FDA 順侅嫚 鞚橂旮瓣赴 歆�鞝�(Breakthrough Device Designation)鞚� 氚涭晿鞀惦媹雼�.
Aethlon Medical (Nasdaq : AEMD), une entreprise de dispositifs m茅dicaux en phase clinique, publiera ses r茅sultats financiers du premier trimestre fiscal 2025 le 13 ao没t 2025 脿 16h15 ET, suivis d'une conf茅rence t茅l茅phonique 脿 16h30 ET.
Le produit principal de la soci茅t茅, le 贬别尘辞辫耻谤颈蹿颈别谤庐, est un dispositif m茅dical exp茅rimental con莽u pour 茅liminer les virus envelopp茅s et les v茅sicules extracellulaires d茅riv茅es des tumeurs de la circulation sanguine. Ce dispositif b茅n茅ficie de la d茅signation de dispositif r茅volutionnaire (Breakthrough Device Designation) de la FDA pour le traitement des patients atteints de cancers avanc茅s non r茅ceptifs aux th茅rapies standard et des virus mortels sans traitements approuv茅s.
Aethlon Medical (Nasdaq: AEMD), ein medizinisches Unternehmen in der klinischen Entwicklungsphase, wird seine Finanzergebnisse f眉r das erste Quartal des Gesch盲ftsjahres 2025 am 13. August 2025 um 16:15 Uhr ET ver枚ffentlichen, gefolgt von einer Telefonkonferenz um 16:30 Uhr ET.
Das Hauptprodukt des Unternehmens, der 贬别尘辞辫耻谤颈蹿颈别谤庐, ist ein experimentelles medizinisches Ger盲t, das entwickelt wurde, um umh眉llte Viren und tumorabgeleitete extrazellul盲re Vesikel aus dem Blutkreislauf zu entfernen. Das Ger盲t hat die FDA Breakthrough Device Designation f眉r die Behandlung von Patienten mit fortgeschrittenem Krebs, die nicht auf Standardtherapien ansprechen, sowie f眉r lebensbedrohliche Viren ohne zugelassene Behandlung erhalten.
- None.
- None.
Management will host a conference call on Wednesday, August 13, 2025, at 4:30 p.m. ET to review financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session.
Interested parties can register for the conference call by navigating to .聽 Please note that registered participants will receive their dial-in number upon registration.
Interested parties without internet access or unable to pre-register may dial in by calling:
PARTICIPANT DIAL IN (TOLL FREE): 1-844-836-8741
PARTICIPANT INTERNATIONAL DIAL IN: 1-412-317-5442
All callers should ask for the Aethlon Medical, Inc. conference call.
A replay of the call will be available approximately one hour after the end of the call through September 13, 2025. The replay can be accessed via Aethlon Medical's website or by dialing 1-877-344-7529 (domestic) or 1-412-317-0088 (international) or
About the Hemopurifier庐
The Aethlon Hemopurifier is an investigational medical device designed to remove enveloped viruses and tumor-derived extracellular vesicles (EVs) from circulation. It is used extracorporeally with a blood pump and combines plasma separation, size exclusion, and affinity binding using a plant lectin resin that targets mannose-rich surfaces found on EVs and viruses. EVs released by solid tumors are believed to play a role in metastasis and the resistance to immunotherapies and chemotherapy. Removal of enveloped viruses and extracellular vesicles has been demonstrated in both vitro studies and human subjects.
The Hemopurifier holds a
The treatment of individuals with advanced or metastatic cancer unresponsive to or intolerant of standard-of-care therapy; and the treatment of life-threatening viruses not addressed with approved therapies.
About Aethlon Medical, Inc.
Aethlon Medical, Inc. (Nasdaq: AEMD) is a clinical-stage medical device company headquartered in
For more information, visit and follow the company on LinkedIn.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect.聽 All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.
Company Contact:
Jim Frakes
Chief Executive Officer and Chief Financial Officer
Aethlon Medical, Inc.
[email protected]
Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
[email protected]
View original content:
SOURCE Aethlon Medical, Inc.
FAQ
When will Aethlon Medical (AEMD) report Q1 2025 earnings?
How can investors access Aethlon Medical's Q1 2025 earnings call?
What is Aethlon Medical's Hemopurifier device designed to do?
What FDA designations does Aethlon Medical's Hemopurifier have?
When will the replay of Aethlon Medical's Q1 2025 earnings call be available?
